SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-040183
Filing Date
2023-02-15
Accepted
2023-02-15 16:01:33
Documents
13
Period of Report
2023-02-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d459493d8k.htm   iXBRL 8-K 28047
2 EX-10.1 d459493dex101.htm EX-10.1 47379
  Complete submission text file 0001193125-23-040183.txt   207997

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20230209.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20230209_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20230209_pre.xml EX-101.PRE 11260
7 EXTRACTED XBRL INSTANCE DOCUMENT d459493d8k_htm.xml XML 3342
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 23635324
SIC: 2834 Pharmaceutical Preparations